| Identification | Back Directory | [Name]
Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)- | [CAS]
1254885-39-6 | [Synonyms]
Minnelide free acid
Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)- | [Molecular Formula]
C21H27O10P | [MOL File]
1254885-39-6.mol | [Molecular Weight]
470.41 |
| Hazard Information | Back Directory | [Uses]
Minnelide free base is a prodrug of Triptolide (HY-32735) that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide free base promotes apoptosis[1]. | [in vivo]
Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) free base leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) free base prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) free base causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice[2]. | [References]
[1] Noel P, et al. Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci. 2019 May;40(5):327-341. DOI:10.1016/j.tips.2019.03.002
[2] Chugh R, et al. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012 Oct 17;4(156):156ra139. DOI:10.1126/scitranslmed.3004334 |
|
|